Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)

This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of AGTC-401 administered to one eye by subretinal injection in individuals with achromatopsia caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the secondary study endpoint will be efficacy.

NCT Number	NCT02599922
Lead Sponsor	Beacon Therapeutics Collaborators: National Eye Institute (NEI)
Conditions	Achromatopsia
Enrollment	32 participants
Start Date	2016-04-11
Primary Completion	2022-07 (estimated)
Study Completion	2026-07 (estimated)
Updated on ClinicalTrials.gov	2022-07-22